Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 7/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.53 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113953 | 0.81 | DYRK1A (0.70) | DYRK1ADYRK1B | |
| SCHEMBL1516821 | 0.81 | KIT (0.70) | KITDYRK1AAAK1SLC2A1MAP3K11 | |
| SCHEMBL7111627 | 0.80 | KIT (0.61) | KITDYRK1AAAK1SLC2A1MAP3K11 | |
| SCHEMBL12763532 | 0.78 | DYRK1A (0.73) | KITDYRK1AAAK1DYRK1BSLC2A1 | |
| SCHEMBL12763545 | 0.77 | DYRK1A (0.80) | KITDYRK1AAAK1SLC2A1MAP3K11 | |
| SCHEMBL1516586 | 0.76 | AAK1 (0.65) | KITDYRK1AAAK1SLC2A1MAP3K11 | |
| SCHEMBL7111817 | 0.76 | AXL (0.60) | DYRK1ADYRK1B | |
| SCHEMBL12762944 | 0.74 | ABL1 (0.59) | KITDYRK1AAAK1DYRK1BMAP3K11 | |
| SCHEMBL12763546 | 0.72 | AAK1 (0.59) | KITDYRK1AAAK1SLC2A1 | |
| SCHEMBL7119150 | 0.72 | MAP3K11 (0.54) | KITDYRK1AAAK1MAP3K11LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003028724-A1 | CHK1 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |